Your Article Summary
See Latest ArticlesUse and cost of erythropoiesis-stimulating agents in patients with cancer
Current Medical Research and Opinion, 06/19/09
Daniel G et al. - Significant differences characterize patterns of use of erythropoiesis-stimulating agents. Duration of therapeutic benefit is an important variable in comparing darbepoetin alfa with epoetin alfa; incorporation of this variable in analyses of costs of therapy may have notable effects on calculated treatment costs. Limitations of the study include the potential for database errors or omissions, lack of detailed disease data, and lack of adjustment for differences in the ages and comorbidities of patients.
Related Articles
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 11/30/09
Relevance Score: 97%%
Obesity linked to specific cancers
Internet Source, 11/05/09
Relevance Score: 97%%
Screening for Cancer
MedLinePlus, 11/02/09
Relevance Score: 97%%
Obesity responsible for 100,000 cancer cases annually
CNN Health, 11/06/09
Relevance Score: 96%%
Coffee link to reduced cancer risk
Internet Source, 11/04/09
Relevance Score: 96%%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/02/09
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09
Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
Clinical Cancer Research, 12/01/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature
Journal Of Pain & Palliative Care Pharmacotherapy, 12/02/09
Imipenem Resistance in Pseudomonas aeruginosa: Emergence, Epidemiology, and Impact on Clinical and Economic Outcomes
Infection Control and Hospital Epidemiology, 12/02/09
Healthcare Costs and Obesity Prevention: Drug Costs and Other Sector-Specific Consequences
PharmacoEconomics, 11/30/09